采取早期预防性干预措施,以应对对第三代EGFR抑制剂获得耐药性的挑战性问题
1Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Chinese medical journal pulmonary and critical care medicine
|August 23, 2023
概括
预防对第三代表皮生长因子受体 (EGFR) - 铁氨酸激酶抑制剂 (TKIs) 的获得性耐药性对于非小细胞肺癌 (NSCLC) 患者至关重要. 早期预防策略可以改善EGFR突变NSCLC治疗这些TKI的结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 第三代表皮生长因子受体 (EGFR) - 铁氨酸激酶抑制剂 (TKI),如奥西默提尼布,对具有EGFR激活突变的非小细胞肺癌 (NSCLC) 显示出希望.
- 对这些技术知识的药物耐药性是第一线和第二线治疗环境中不可避免的挑战.
- 管理获得的耐药性对于提高EGFR突变NSCLC患者的存活率至关重要.
研究的目的:
- 探索在EGFR突变NSCLC中对第三代EGFR-TKIs获得的耐药性管理的策略.
- 强调主动,预防性干预的重要性,而不是被动的抗药管理.
- 讨论科学理由和机制驱动的方法来延迟或预防对第三代EGFR-TKIs的获得性耐药性,特别是 osimertinib.
主要方法:
- 对EGFR-TKI耐药机制的现有文献的审查.
- 对EGFR突变NSCLC治疗结果的临床数据的分析.
- 探索组合疗法和预防策略.
主要成果:
- 目前克服获得性抗性的方法往往是被动和反应性的.
- 使用可容忍的组合疗法进行早期预防干预具有显著的潜力.
- 延迟或预防耐药性可以显著改善EGFR突变NSCLC的治疗结果.
结论:
- 积极的战略对于对抗对第三代EGFR-TKI获得的耐药性至关重要.
- 制定和实施预防措施可以提高这些向治疗的长期疗效.
- 对机制驱动的预防干预措施的进一步研究是有必要的,以改善EGFR突变NSCLC患者的存活率.
更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Barrett Esophagus-II: Clinical Manifestations and Management
192
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
192
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Barrett Esophagus-I: Introduction
123
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
123
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
203
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
203


